



LKT Laboratories, Inc.

## Olaparib

Phone: 888-558-5227  
651-644-8424  
Fax: 888-558-7329  
Email: [getinfo@lktlabs.com](mailto:getinfo@lktlabs.com)  
Web: [lktlabs.com](http://lktlabs.com)

### Product Information

Product ID O4402

CAS No. 763113-22-0

**Chemical Name**

Synonym AZD2281, KU-0059436

Formula  $C_{24}H_{23}FN_4O_3$

Formula Wt. 434.47

**Melting Point**


Purity  $\geq 98\%$

Solubility DMSO (10 mg/ml), DMF (3 mg/ml)

Store Temp 4°C

Ship Temp Ambient

**Description** Olaparib is an inhibitor of poly(ADP-ribose) polymerase (PARP 1/2) that prevents DNA repair. Olaparib displays benefit in clinical trials of BRCA mutation-harboring ovarian and breast cancers as well as prostate, pancreatic, and non-small cell lung cancers (NSCLC). In animal models with ovarian cancer xenografts, olaparib increases apoptosis and decreases proliferation to inhibit tumor growth. TEST!!!!!!



### Pricing and Availability

*Bulk quantities available upon request*

Product ID	Size	List Price
O4402	5 mg	\$60.00
O4402	10 mg	\$81.00
O4402	25 mg	\$112.40

**References** Lee JM, Ledermann JA, Kohn EC. PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. Ann Oncol. 2013 Nov 12. [Epub ahead of print]. PMID: 24225019.

Olaparib Enters Phase III Clinical Testing. Cancer Discov. 2013 Nov;3(11):1210. PMID: 24203936.

Postel-Vinay S, Bajrami I, Friboulet L, et al. A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer. Oncogene. 2013 Nov 21;32(47):5377-87. PMID: 23934192.

Kortmann U, McAlpine JN, Xue H, et al. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts. Clin Cancer Res. 2011 Feb 15;17(4):783-91. PMID: 21097693.

**Caution:** This product is intended for laboratory and research use only. It is not for human or drug use.